Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis.

[1]  A. Schuchat,et al.  Population-Based Surveillance in San Francisco and Atlanta Trends in Incidence and Antimicrobial Resistance of Early-Onset Sepsis: , 2005 .

[2]  M. Pearlman.  Prevention of early-onset group B streptococcal disease in newborns. , 2003, Obstetrics and gynecology.

[3]  Stephanie Schrag,et al.  Prevention of Perinatal Group B Streptococcal Disease Revised Guidelines from CDC , 2002 .

[4]  R. Goldenberg,et al.  The management of preterm labor. , 2002, Obstetrics and gynecology.

[5]  K. O'Brien,et al.  Trends in incidence and antimicrobial resistance of early-onset sepsis: population-based surveillance in San Francisco and Atlanta. , 2002, Pediatrics.

[6]  R. Edwards,et al.  Intrapartum Antibiotic Prophylaxis 1: Relative Effects of Recommended Antibiotics on Gram‐Negative Pathogens , 2002, Obstetrics and gynecology.

[7]  H. Davies,et al.  Perinatal Antibiotic Usage and Changes in Colonization and Resistance Rates of Group B Streptococcus and Other Pathogens , 2002, Obstetrics and gynecology.

[8]  G. Briggs,et al.  Antepartum use of antibiotics and early-onset neonatal sepsis: the next 4 years. , 2002, American journal of obstetrics and gynecology.

[9]  W. Poole,et al.  Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. , 2002, The New England journal of medicine.

[10]  M. Lipsitch,et al.  Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  P. Sánchez,et al.  Prevention of neonatal group B streptococcal disease: A combined intrapartum and neonatal protocol. , 2002, American journal of obstetrics and gynecology.

[12]  J. Martin,et al.  Births: final data for 2000. , 2002, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[13]  A. Schuchat,et al.  Public health issues related to infection in pregnancy and cerebral palsy. , 2002, Mental retardation and developmental disabilities research reviews.

[14]  K. O'Brien,et al.  Early-onset neonatal sepsis in the era of group B streptococcal prevention. , 2001, Pediatrics.

[15]  E. Eichenwald,et al.  No increase in rates of early-onset neonatal sepsis by non-group B Streptococcus or ampicillin-resistant organisms. , 2001, American journal of obstetrics and gynecology.

[16]  D. Ballot,et al.  Is prophylaxis of early-onset group B streptococcal disease appropriate for South Africa? , 2001, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[17]  R. Auckenthaler,et al.  Choosing a strategy to prevent neonatal early‐onset group B streptococcal sepsis: economic evaluation , 2001, BJOG : an international journal of obstetrics and gynaecology.

[18]  D. Soper,et al.  Antibiotic resistance patterns of group B streptococci in late third-trimester rectovaginal cultures. , 2001, American journal of obstetrics and gynecology.

[19]  M. Lipsitch,et al.  Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  Y. Carmeli,et al.  Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  S. Kenyon,et al.  Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial , 2001, The Lancet.

[22]  W. Tarnow-Mordi,et al.  Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial , 2001, The Lancet.

[23]  A. Schuchat,et al.  Introduction of the new Centers for Disease Control and Prevention group B streptococcal prevention guideline at a large West Coast health maintenance organization. , 2001, American journal of obstetrics and gynecology.

[24]  Ronald N. Jones,et al.  Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere. , 2000, American journal of obstetrics and gynecology.

[25]  D. Kasper,et al.  Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. , 2000, The Journal of infectious diseases.

[26]  C. Crowther,et al.  Universal antenatal group B streptococcus screening? The opinions of obstetricians and neonatologists within Australia , 2000, Australian and New Zealand journal of obstetrics and gynaecology.

[27]  J. Troendle,et al.  Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995-1998. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  A. Harris,et al.  Control group selection is an important but neglected issue in studies of antibiotic resistance. , 2000, Annals of internal medicine.

[29]  D. Luthy,et al.  Performance of a group B streptococcal prophylaxis protocol combining high-risk treatment and low-risk screening. , 2000, American journal of obstetrics and gynecology.

[30]  E. Main,et al.  Prevention of early-onset invasive neonatal group B streptococcal disease in a private hospital setting: the superiority of culture-based protocols. , 2000, American journal of obstetrics and gynecology.

[31]  M. Krohn,et al.  Effect of a Screening–based Prevention Policy on Prevalence of Early‐Onset Group B Streptococcal Sepsis , 2000, Obstetrics and gynecology.

[32]  A. Schuchat,et al.  Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. , 2000, The New England journal of medicine.

[33]  B. Stoll,et al.  Risk Factors and Opportunities for Prevention of Early-Onset Neonatal Sepsis: A Multicenter Case-Control Study , 1999, Pediatrics.

[34]  M. Hod,et al.  Effect of antibiotic therapy in preterm premature rupture of the membranes on neonatal mortality and morbidity. , 2000, American journal of perinatology.

[35]  J. Hadler,et al.  From the Centers for Disease Control and Prevention: early-onset group B streptococcal disease--United States, 1998-1999. , 2000, JAMA.

[36]  B. Sibai,et al.  Antibiotic use in pregnancy and drug-resistant infant sepsis. , 1999, American journal of obstetrics and gynecology.

[37]  J. N. Martin,et al.  Neonatal sepsis and death caused by resistant Escherichia coli: possible consequences of extended maternal ampicillin administration. , 1999, American journal of obstetrics and gynecology.

[38]  D. Isaacs,et al.  Intrapartum antibiotics and early onset neonatal sepsis caused by group B Streptococcus and by other organisms in Australia. Australasian Study Group for Neonatal Infections. , 1999, The Pediatric infectious disease journal.

[39]  J. Gould,et al.  Risk Factors for Early-onset Group B Streptococcal Sepsis: Estimation of Odds Ratios by Critical Literature Review , 1999, Pediatrics.

[40]  L. Ayers,et al.  Bloodstream Infections in a Neonatal Intensive-Care Unit: 12 Years' Experience With an Antibiotic Control Program , 1999, Infection Control & Hospital Epidemiology.

[41]  D. Scholes,et al.  Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. , 1999, JAMA.

[42]  G. Bevilacqua.  [Prevention of perinatal infection caused by group B beta-hemolytic streptococcus]. , 1999, Acta bio-medica de L'Ateneo parmense : organo della Societa di medicina e scienze naturali di Parma.

[43]  D. Kasper,et al.  Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. , 1999, The Journal of infectious diseases.

[44]  C. Strom,et al.  Intrapartum antibiotic prophylaxis increases the incidence of gram-negative neonatal sepsis. , 1999, Infectious diseases in obstetrics and gynecology.

[45]  A. Schuchat,et al.  Impact of a risk-based prevention policy on neonatal group B streptococcal disease. , 1998, American journal of obstetrics and gynecology.

[46]  T. Asrat,et al.  Potential consequences of widespread antepartal use of ampicillin. , 1998, American journal of obstetrics and gynecology.

[47]  T. Lieu,et al.  Neonatal Group B Streptococcal Infection in a Managed Care Population , 1998, Obstetrics and gynecology.

[48]  Francesc Botet,et al.  Administration of antibiotics to patients with rupture of membranes at term, A prospective, randomized, multicentric study , 1998 .

[49]  H. Jeffery,et al.  Eight-Year Outcome of Universal Screening and Intrapartum Antibiotics for Maternal Group B Streptococcal Carriers , 1998, Pediatrics.

[50]  K. Butler,et al.  Group B streptococcus (GBS) colonisation among expectant Irish mothers. , 1998, Irish medical journal.

[51]  N. F. Jacobs,et al.  Neonatal early-onset Escherichia coli disease. The effect of intrapartum ampicillin. , 1998, Archives of pediatrics & adolescent medicine.

[52]  S. Allen.  Management of Asymptomatic Term Neonates Whose Mothers Received Intrapartum Antibiotics—Part 2: Diagnostic Tests and Management Strategies , 1997, Clinical pediatrics.

[53]  L. Wright,et al.  Revised guidelines for prevention of early-onset group B streptococcal (GBS) infection. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. , 1997, Pediatrics.

[54]  E. Eichenwald,et al.  Perinatally transmitted neonatal bacterial infections. , 1997, Infectious disease clinics of North America.

[55]  D. Kasper,et al.  Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. , 1996, The Journal of clinical investigation.

[56]  A. Schuchat,et al.  Prevention of perinatal group B streptococcal disease : a public health perspective , 1996 .

[57]  A. Fattom,et al.  Prevention of Systemic Infections Caused by Group B Streptococcus and Staphylococcus aureus by Multivalent Polysaccharide‐Protein Conjugate Vaccines , 1995, Annals of the New York Academy of Sciences.

[58]  T. Miyoshi,et al.  Neonatal Group B Streptococcal Sepsis During 2 Years of a Universal Screening Program , 1994, Obstetrics and gynecology.

[59]  Boe Nm.  Group B streptococcal infections in pregnancy. , 1994 .

[60]  A. Schuchat,et al.  Multistate case-control study of maternal risk factors for neonatal group B streptococcal disease. The Active Surveillance Study Group. , 1994, The Pediatric infectious disease journal.

[61]  R. Gibbs,et al.  Adverse perinatal outcome and resistant Enterobacteriaceae after antibiotic usage for premature rupture of the membranes and group B streptococcus carriage , 1993, Obstetrics and gynecology.

[62]  M. Mustafa,et al.  Gram-negative enteric bacillary meningitis: a twenty-one-year experience. , 1993, The Journal of pediatrics.

[63]  C. Broome,et al.  American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn: Guidelines for prevention of group B streptococcal (GBS) infection by chemoprophylaxis. , 1992, Pediatrics.

[64]  K. Boyer,et al.  Prevention of early‐onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis , 1986, The New England journal of medicine.

[65]  K. Boyer,et al.  Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease. I. Epidemiologic rationale. , 1983, The Journal of infectious diseases.

[66]  E. Mason,et al.  Ampicillin prevents intrapartum transmission of group B streptococcus. , 1979, JAMA.